SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025
Continued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025